

**Don't just sense presence. Sense a threat.**

Only the Aptima® HPV assay and Aptima® HPV 16 18/45 Genotype assay detect both HPV presence and activity to target the infections most likely to lead to cervical disease — helping physicians maximize the benefits of screening while minimizing potential harm.

**Run the Aptima HPV and HPV genotype assays simultaneously – from a single patient sample – on the Panther® system, and deliver results for both assays at once**

- ▶ The Aptima HPV genotype assay targets HPV types 16, 18 and 45, which show higher carcinogenic potential relative to all other high-risk HPV types.<sup>1</sup>
- ▶ The addition of HPV type 45 to the Aptima HPV genotype assay identifies more women at risk for adenocarcinoma, with minimal impact to colposcopy rate.<sup>2</sup>


**To support better patient care, the Aptima HPV assay demonstrates improved specificity while offering the same excellent sensitivity as compared to DNA-based tests<sup>3</sup>**

**The Aptima HPV assay showed 24% fewer false positives than DNA-based tests in the NILM arm of the CLEAR trial.<sup>3</sup>**

- ▶ **Minimizes potential for overtreatment**
- ▶ **Minimizes difficult patient conversations**


**With longer intervals between cervical cancer screenings, identifying patients at risk requires excellent sensitivity.**

**Clinical sensitivity for ≥ CIN3<sup>4-19,\*</sup>**



# The right targets to identify the right treatment

The Aptima HPV assay identifies high-risk HPV infections by targeting E6/E7 mRNA.<sup>9</sup> Studies show that targeting E6/E7 mRNA identifies both the presence and activity of a high-risk HPV infection.<sup>20,21</sup>



The Aptima HPV assay offers a combination of the same excellent sensitivity and improved specificity as compared with DNA-based tests.<sup>3</sup> These performance characteristics align with current clinical practice guidelines, which are designed to maximize the benefits of cervical cancer screening while minimizing potential harm.<sup>23</sup>

#### References:

1. Guan, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. *Intl. J Cancer*. 2012;131(10):2349-2359.
2. de Sanjose, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol*. 2010;11(11):1048-1056.
3. Aptima HPV Assay [package insert], San Diego, CA; Hologic, Inc., 2014. Table #13.
4. Szarewski, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. *Cancer Epidemiol Biomarkers Prev*. 2008;17(11):3033-3042.
5. Dockte, et al. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. *J Clin Virol*. 2009;45(S1):S55-S61.
6. Reuschenbach, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. *Gynecol Oncol*. 2010;119(1): 98-105.
7. Clad, et al. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. *J Clin Microbiol*. 2011;49(3):1071-1076.
8. Ratnam, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. *J Clin Microbiol*. 2011;49(2):557-564.
9. Aptima HPV Assay [package insert], San Diego, CA; Hologic, Inc., 2014.
10. Ovestad, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. *Gynecol Oncol*. 2011;123(2):278-283.
11. Szarewski, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. *J Clin Microbiol*. 2012;50(6):1867-1873.
12. Eaton, et al. Comparison of the Aptima HPV assay and the cobas HPV test in an ASC-US population [abstract]. Paper presented at: 28th International Papillomavirus Conference; November 30-December 6, 2012; San Juan, Puerto Rico.
13. Cuschieri, et al. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. *J Clin Virol*. 2014;59(2):104-108.
14. Cubie, et al. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). *J Clin Pathol*. 2014;67(6):458-463.
15. Wu, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. *Intl J Gynecol Cancer*. 2010;20(8):1411-1414.
16. Monsonego, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. *Intl J Cancer*. 2011;129(3):691-701.
17. Iftner, et al. Comparison of Aptima and HC2 in a routine screening trial in Germany with follow up [abstract]. Paper presented at: 28th International Papillomavirus Conference; November 30-December 6, 2012; San Juan, Puerto Rico.
18. Cuzick, et al. Comparing the performance of six human papillomavirus tests in a screening population. *Br J Cancer*. 2013;108:908-913.
19. Nieves, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. *Int J Gynecol Cancer*. 2013;23(3):513-518.
20. Cuschieri, et al. Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. *J Med Virol*. 2004;73:65-70.
21. Tinelli, et al. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical. *J Clin Virol*. 2005;32(Suppl 1):S7-S15.
22. Doorbar, J. The papillomavirus life cycle. *J Clin Virol*. 2005;32(Suppl 1):S7-S15.
23. Saslow, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *Am J Clin Pathol*. 2012;137:516-542.

SS-00267-001 Rev. 001 © 2015 Hologic, Inc. All rights reserved. Hologic, Science of Sure, Aptima, Panther and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to [diagnostic.solutions@hologic.com](mailto:diagnostic.solutions@hologic.com).

**Aptima® HPV**  
Assays